382 related articles for article (PubMed ID: 24574398)
41. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
[TBL] [Abstract][Full Text] [Related]
42. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
43. Immunostimulatory Profile of Cancer Cell Death by the AdV-Lumc007-Derived Oncolytic Virus 'GoraVir' in Cultured Pancreatic Cancer Cells.
Bots STF; Landman SL; Rabelink MJWE; van den Wollenberg DJM; Hoeben RC
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851497
[TBL] [Abstract][Full Text] [Related]
44. Advances in oncolytic adenovirus therapy for pancreatic cancer.
Nattress CB; Halldén G
Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
[TBL] [Abstract][Full Text] [Related]
45. 4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.
Hufnagel S; Xu H; Colemam MF; Valdes SA; Liu KA; Hursting SD; Cui Z
Cancer Chemother Pharmacol; 2022 Jan; 89(1):59-69. PubMed ID: 34698902
[TBL] [Abstract][Full Text] [Related]
46. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.
Dempe S; Lavie M; Struyf S; Bhat R; Verbeke H; Paschek S; Berghmans N; Geibig R; Rommelaere J; Van Damme J; Dinsart C
Cancer Immunol Immunother; 2012 Nov; 61(11):2113-23. PubMed ID: 22576056
[TBL] [Abstract][Full Text] [Related]
47. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
Hartley A; Kavishwar G; Salvato I; Marchini A
Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
[TBL] [Abstract][Full Text] [Related]
48. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
49. Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
[TBL] [Abstract][Full Text] [Related]
50. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
[TBL] [Abstract][Full Text] [Related]
51. Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis.
Lavie M; Struyf S; Stroh-Dege A; Rommelaere J; Van Damme J; Dinsart C
Virology; 2013 Dec; 447(1-2):221-32. PubMed ID: 24210118
[TBL] [Abstract][Full Text] [Related]
52. The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.
Angelova AL; Witzens-Harig M; Galabov AS; Rommelaere J
Front Oncol; 2017; 7():93. PubMed ID: 28553616
[TBL] [Abstract][Full Text] [Related]
53. Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells.
Heinrich B; Goepfert K; Delic M; Galle PR; Moehler M
Onco Targets Ther; 2013; 6():1119-27. PubMed ID: 23986643
[TBL] [Abstract][Full Text] [Related]
54. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death.
Hayashi K; Nikolos F; Lee YC; Jain A; Tsouko E; Gao H; Kasabyan A; Leung HE; Osipov A; Jung SY; Kurtova AV; Chan KS
Nat Commun; 2020 Dec; 11(1):6299. PubMed ID: 33288764
[TBL] [Abstract][Full Text] [Related]
55. Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
Karelia DN; Kim S; K Pandey M; Plano D; Amin S; Lu J; Sharma AK
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067020
[TBL] [Abstract][Full Text] [Related]
56. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.
Angelova AL; Geletneky K; Nüesch JP; Rommelaere J
Front Bioeng Biotechnol; 2015; 3():55. PubMed ID: 25954743
[TBL] [Abstract][Full Text] [Related]
57. Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death.
Nuccitelli R; McDaniel A; Anand S; Cha J; Mallon Z; Berridge JC; Uecker D
J Immunother Cancer; 2017; 5():32. PubMed ID: 28428881
[TBL] [Abstract][Full Text] [Related]
58. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
Eisenberg DP; Adusumilli PS; Hendershott KJ; Yu Z; Mullerad M; Chan MK; Chou TC; Fong Y
J Gastrointest Surg; 2005 Nov; 9(8):1068-77; discussion 1077-9. PubMed ID: 16269377
[TBL] [Abstract][Full Text] [Related]
59. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity.
Raykov Z; Grekova S; Leuchs B; Aprahamian M; Rommelaere J
Int J Cancer; 2008 Jun; 122(12):2880-4. PubMed ID: 18360875
[TBL] [Abstract][Full Text] [Related]
60. Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.
Frehtman V; Wohlfarth D; Müller M; Krebs O; Leuchs B
Appl Microbiol Biotechnol; 2023 Aug; 107(15):4777-4787. PubMed ID: 37209160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
